| PUBLICATIONS (Ranked by Impact Factor of the Journal) | LABORATORY RESEARCH Connexin-43 in the Osteogenic BM Niche Regulates Its Cellular Composition and the Bidirectional Traffic of Hematopoietic Stem Cells and Progenitors To elucidate the biologic function of connexin-43 (Cx43) in a hematopoietic microenvironment and its influence in hematopoietic stem cell activity, researchers studied the hematopoietic function in an in vivo model of constitutive deficiency of Cx43 in osteoblasts and osteogenic progenitors. [Blood] Abstract Spry1 As a Novel Regulator of Erythropoiesis, EPO/EPOR Target, and Supressor of Jak2 Studies implicate Spry1 as a novel regulator of erythropoiesis during anemia, transducer of erythropoietin receptor (EPOR) signals and candidate suppressor of Jak2 activity. [Blood] Abstract Heme-Regulated eIF2α Kinase Activated Atf4 Signaling Pathway in Oxidative Stress and Erythropoiesis Scientists report the role of the heme-regulated eIF2α kinase-activated Atf4 signaling pathway in reducing oxidative stress and in promoting erythroid differentiation during erythropoiesis. [Blood] Abstract In Vivo Suppression of HIV by Antigen Specific T Cells Derived from Engineered Hematopoietic Stem Cells Researchers sought to genetically manipulate human hematopoietic stem cells such that they differentiate into mature cytotoxic T lymphocytes that will kill HIV infected cells. [PLoS Pathog] Abstract | Press Release Lipid Raft Redistribution and Morphological Cell Polarization Are Separable Processes Providing a Basis for Hematopoietic Stem and Progenitor Cell Migration Scientists addressed impacts of protein synthesis, hematopoietic stem and progenitor cells (HSPC) trafficking, cytoskeleton organization or lipid raft integrity on the establishment and maintenance of the cell polarity of human HSPCs. [Int J Biochem Cell Biol] Abstract Stromal-Derived IL-6 Alters the Balance of Myeloerythroid Progenitors during Toxoplasma gondii Infection Data suggest that bone marrow stromal cells regulate the hematopoietic changes during inflammation via IL-6. [J Leukoc Biol] Abstract Efficient Commitment to Functional CD34+ Progenitor Cells from Human Bone Marrow Mesenchymal Stem-Cell-Derived Induced Pluripotent Stem Cells Researchers propose that CD34+ progenitor cells, which retain hematopoietic and endothelial cell potential, could be efficiently obtained from induced pluripotent stem cells derived from human bone marrow mesenchymal stem cells with defined factors. [PLoS One] Abstract Deferasirox Exposure Induces Reactive Oxygen Species and Reduces Growth and Viability of Myelodysplastic Hematopoietic Progenitors The effect of deferasirox on CD34+ hematopoietic progenitors from myelodysplastic syndrome patients was examined. [Leuk Res] Abstract Rapamycin Enhances Dimethyl Sulfoxide-Mediated Growth Arrest in Human Myelogenous Leukemia Cells Scientists tested for the possible beneficial effects of the combination of rapamycin and dimethyl sulfoxide on growth arrest and differentiation of acute myelogenous leukemia cells. [Leuk Lymphoma] Abstract CLINICAL RESEARCH High Activity of Sorafenib in FLT3-ITD-Positive Acute Myeloid Leukemia (AML) Synergizes with Allo-Immune Effects to Induce Sustained Responses Researchers evaluated sorafenib monotherapy in 65 FLT3-ITD-postive AML patients treated at 23 centers. [Leukemia] Abstract Gene Immunotherapy of Chronic Lymphocytic Leukemia: A Phase I Study of Intranodally Injected Adenovirus Expressing a Chimeric CD154 Molecule The results of a first-in-man Phase I trial of intranodal direct injection of adenovirus encoding chimeric CD154 in patients with chronic lymphocytic leukemia to evaluate toxicity, safety, and tolerability are reported. [Cancer Res] Abstract |
| INDUSTRY NEWS | VistaGen Licenses Breakthrough Stem Cell Culture Technology to Speed Development of Drug Screening and Cell Therapy for Immune System Disorders VistaGen Therapeutics, Inc. has licensed breakthrough stem cell culture technology from the McEwen Centre for Regenerative Medicine. VistaGen will be utilizing the licensed technology to develop hematopoietic precursor stem cells from human pluripotent stem cells, with the goal of developing drug screening and cell therapy applications for human blood system disorders. [VistaGen Therapeutics, Inc.] Press Release Seattle Genetics and Millennium to Collaborate with Ventana on Companion Diagnostic for ADCETRIS(TM) in CD30-Positive Malignancies Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company announced that they have formed a collaboration with Ventana Medical Systems, Inc. (Ventana). [Seattle Genetics, Inc.] Press Release Cyclacel Pharmaceuticals Announces Grant of New U.S. Patent Covering Sapacitabine Cyclacel Pharmaceuticals, Inc. announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 8,124,593 which grants claims to a specified method of administration of sapacitabine with patent exclusivity until July 2030. [Cyclacel Pharmaceuticals, Inc.] Press Release |
|
|
|